TRT and Hematocrit: Managing Red Blood Cell Levels on Testosterone

What Is Hematocrit and Why Does It Matter?

Hematocrit (Hct) is a measure of the proportion of red blood cells (RBCs) in your total blood volume. Normal hematocrit for adult men is approximately 41–53%. Red blood cells carry oxygen from the lungs to tissues, so having enough is critical — but too many creates problems.

When hematocrit rises above normal (a condition called erythrocytosis or polycythemia), blood becomes more viscous (thicker). Thick blood flows less easily through vessels, increases clotting risk, and can raise the risk of:

• Deep vein thrombosis (DVT)
• Pulmonary embolism (PE)
• Stroke
• Heart attack

This is why hematocrit monitoring is a standard component of TRT management.

Why Does Testosterone Raise Hematocrit?

Testosterone stimulates red blood cell production through several mechanisms:

• Erythropoietin (EPO) stimulation: Testosterone increases EPO production in the kidneys. EPO signals the bone marrow to produce more red blood cells.
• Direct bone marrow stimulation: Testosterone also has direct effects on bone marrow, promoting erythroid progenitor cell differentiation.
• Hepcidin suppression: Testosterone lowers hepcidin, a hormone that normally limits iron absorption and red blood cell production. With less hepcidin, more iron is available for RBC synthesis.

These are the same mechanisms that made testosterone a historic treatment for anemia before modern therapies were developed. In the context of TRT, this RBC-stimulating effect is beneficial at moderate levels but requires monitoring to prevent excessive erythrocytosis.

How Common Is Erythrocytosis on TRT?

Erythrocytosis is the most common adverse effect of TRT. Studies report rates of 5–25% depending on the definition used and the TRT formulation. Injectable testosterone (particularly long-acting esters like testosterone cypionate and enanthate) produces higher peak testosterone levels and tends to cause greater hematocrit elevations than transdermal gels or patches.

Risk factors for erythrocytosis on TRT include:

• Injectable testosterone (vs. transdermal)
• Higher testosterone doses
• Sleep apnea (already elevates RBC production due to hypoxia)
• Smoking
• Living at high altitude
• Older age
• Pre-existing higher baseline hematocrit

Safe Hematocrit Thresholds on TRT

The Endocrine Society and American Urological Association (AUA) guidelines recommend:

• Safe range: Hematocrit below 52–54%
• Dose reduction or hold: Consider dose adjustment if hematocrit exceeds 52–54%
• Discontinue or hold TRT: Hematocrit ≥55% requires stopping therapy until levels normalize

It's important to note that mildly elevated hematocrit (e.g., 50–53%) in the context of TRT does not automatically indicate clinical erythrocytosis requiring intervention — context matters. A man who started at a baseline hematocrit of 47% reaching 52% is different from one already at 50% who climbs to 55%. Your clinician will assess trends alongside other factors.

Monitoring Schedule

Standard monitoring protocol for hematocrit during TRT:

• Baseline: Before starting therapy
• 3 months: After initiating TRT or any dose change
• Every 6–12 months: Once stable on therapy

A complete blood count (CBC) — which includes hemoglobin, hematocrit, and RBC count — is typically checked at these intervals. Ferritin and iron studies may also be helpful to assess iron stores, particularly if erythrocytosis is being managed.

Strategies for Managing Elevated Hematocrit

1. Dose Reduction

Lowering the testosterone dose reduces the erythropoietic stimulus. This is often the first step when hematocrit climbs above threshold. The trade-off is potentially lower symptom relief, so the dose adjustment needs to balance erythrocytosis management with therapeutic benefit.

2. Switch to a Different Delivery Method

Transdermal formulations (gels, creams, patches) produce lower and more stable testosterone peaks compared to injections, which tend to generate supraphysiologic spikes immediately after injection. Many men who develop erythrocytosis on injections maintain normal hematocrit after switching to daily topical testosterone.

Learn about the differences between delivery methods in our TRT injections vs. pellets vs. cream guide.

3. More Frequent, Smaller Injections

For men who prefer injections, switching from biweekly to weekly or even twice-weekly injections reduces peak testosterone levels while maintaining the same total weekly dose. Lower peaks mean less EPO stimulation and less hematocrit elevation.

4. Therapeutic Phlebotomy

Blood donation or therapeutic phlebotomy (essentially the same process) directly removes excess red blood cells. Many men on TRT donate blood every 2–3 months, which serves a dual purpose: managing their hematocrit and providing a useful blood supply. However, the FDA restricts blood donation by TRT users in some situations, so therapeutic phlebotomy ordered through a physician may be required.

Note that repeated phlebotomy can deplete iron stores, so ferritin should be monitored and iron supplementation avoided unless genuinely deficient.

5. Treat Underlying Sleep Apnea

Obstructive sleep apnea (OSA) is strongly associated with elevated hematocrit because nighttime oxygen dips drive EPO production. Many men with OSA are undiagnosed. Treating OSA with CPAP can significantly reduce hematocrit and may even partially alleviate the need for TRT in men whose low testosterone is partly driven by poor sleep.

6. Stay Well Hydrated

Dehydration concentrates blood, artificially elevating hematocrit readings. While hydration won't reverse true erythrocytosis, ensuring adequate fluid intake ensures your hematocrit reading reflects your actual RBC mass rather than dehydration-induced hemoconcentration.

When to Pause or Stop TRT

A hematocrit consistently above 54–55% is grounds for pausing TRT until levels normalize. After stopping, hematocrit typically returns toward baseline within 4–8 weeks. Once normalized, therapy can often be restarted at a lower dose, with a different delivery method, or with more frequent phlebotomy as part of the management plan.

Men with a history of blood clots (DVT, PE), stroke, or known thrombophilia (clotting disorders) are generally not good candidates for TRT, or require extremely careful management and specialist involvement.

Erythrocytosis vs. Other Causes of High Hematocrit

Not all elevated hematocrit on TRT is due to testosterone itself. Before attributing high hematocrit solely to TRT, other causes should be excluded:

• Polycythemia vera (a bone marrow disorder causing unregulated RBC overproduction)
• Undiagnosed or undertreated sleep apnea
• Smoking
• High altitude living
• Dehydration
• Lung disease with chronic hypoxia

A physician evaluation including EPO level, bone marrow assessment (if indicated), and review of the clinical picture can distinguish TRT-related erythrocytosis from primary polycythemia vera, which requires different management.

The Bottom Line

Hematocrit elevation is common with TRT but is typically manageable with monitoring, dose adjustments, or phlebotomy. It should not be a reason to avoid testosterone therapy for genuinely hypogonadal men — but it does require ongoing clinical oversight. The combination of appropriate dosing, the right delivery method, and regular blood work keeps most men safely within normal ranges while enjoying the full benefits of TRT.

For a comprehensive look at testosterone therapy and cardiovascular health, read our article on testosterone and heart health in men.

According to the AUA's testosterone deficiency guidelines, hematocrit monitoring is a standard of care for all men on testosterone therapy.